<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448680</url>
  </required_header>
  <id_info>
    <org_study_id>LFB-FVIIa-007-14</org_study_id>
    <nct_id>NCT02448680</nct_id>
  </id_info>
  <brief_title>A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa</brief_title>
  <acronym>PERSEPT2</acronym>
  <official_title>A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients From Birth to &lt;12 Years Old With Inhibitors to Factor VIII or IX: PerSept 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LFB USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LFB USA, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate&#xD;
      dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the&#xD;
      treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII&#xD;
      or IX in 12 patients ( birth to &lt;6 years old), and 12 patients (≥6 years old to &lt;12 years&#xD;
      old).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa&#xD;
      (Recombinant) in Congenital Hemophilia A or B Pediatric Patients from birth to &lt;12 years old&#xD;
      with Inhibitors to Factor VIII or IX: PerSept 2&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2015</start_date>
  <completion_date type="Actual">August 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Successfully Treated Mild/Moderate Bleeding Episodes Per FDA Requirement.</measure>
    <time_frame>12 hours after first administration of study drug</time_frame>
    <description>For the primary efficacy endpoint, successful treatment of mild/moderate bleeding episode was defined as meeting all of the following:&#xD;
&quot;Good&quot; or &quot;excellent&quot; response noted by the patient/parent/legal guardian or other caregiver, depending on patient's age and maturity&#xD;
Study drug treatment: No further treatment with LR769 beyond timepoint where a &quot;good&quot; or &quot;excellent&quot; response for this bleeding episode was noted&#xD;
No other hemostatic treatment needed for this bleeding episode&#xD;
No administration of blood products that would indicate continuation of bleeding beyond timepoint where a &quot;good&quot; or &quot;excellent&quot; response for this bleeding episode was noted&#xD;
No increase of pain beyond timepoint where a &quot;good&quot; or &quot;excellent&quot; response for this bleeding episode was noted that could not be explained other than as continuation of bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Successfully Treated Bleeding Episodes (Mild/Moderate/Severe) Per EMA Definition</measure>
    <time_frame>12 hours after first administration of study drug</time_frame>
    <description>&quot;Good&quot; or &quot;excellent&quot; response noted by the patient/caregiver for mild/moderate bleeding episodes;&#xD;
&quot;Good&quot; or &quot;excellent&quot; response noted by the physician for severe bleeding episodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported &quot;Good&quot; or &quot;Excellent&quot; Response for Mild/Moderate Bleeding Episodes</measure>
    <time_frame>12 hour after first administration of study drug</time_frame>
    <description>Based on Patient-Reported &quot;Good&quot; or &quot;Excellent&quot; responses as per the below descriptions:&#xD;
Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.&#xD;
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage). No additional infusion of study drug was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Patient Assessment of a &quot;Good&quot; or &quot;Excellent&quot; Response for Mild/Moderate Bleeding Episodes</measure>
    <time_frame>Within 24 hours of Bleeding Episode</time_frame>
    <description>Categories of Response to Treatment are Described as Follows:&#xD;
None: No noticeable effect of the treatment on the bleed or worsening of patient's condition. Continuation of treatment with the study drug was needed.&#xD;
Moderate: Some effect of the treatment on the bleed was noticed, e.g., pain decreased or bleeding signs improved, but bleed continued and required continued treatment with the study drug.&#xD;
Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.&#xD;
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode</measure>
    <time_frame>Within 24 hours of Bleeding Episode</time_frame>
    <description>The number of study drug administrations with non-missing dose information in order to treat one mild/moderate bleeding episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode</measure>
    <time_frame>Within 24 hours of Bleeding Episode</time_frame>
    <description>The total amount of study drug administered in order to treat one mild/moderate bleeding episode.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mild/Moderate Bleeding Episodes With Successful Pain Relief</measure>
    <time_frame>12 hour after first administration of study drug</time_frame>
    <description>Successful pain relief was defined as a Visual Analogue Scale (VAS: 0-100; 0: no pain at all; 100: the worst pain ever possible) pain score at 12 hours after initial study drug administration that was less than the pain score at the start of treatment with study drug.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hemophilia A With Inhibitors</condition>
  <condition>Hemophilia B With Inhibitors</condition>
  <arm_group>
    <arm_group_label>Coagulation Factor VIIa (Recombinant): 75 µg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 µg/kg treatment regimen for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coagulation Factor VIIa (Recombinant): 225 µg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>225 µg/kg treatment regimen for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Coagulation FVIIa (Recombinant)</intervention_name>
    <description>A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX</description>
    <arm_group_label>Coagulation Factor VIIa (Recombinant): 225 µg/kg</arm_group_label>
    <arm_group_label>Coagulation Factor VIIa (Recombinant): 75 µg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  be male with a diagnosis of congenital hemophilia A or B of any severity&#xD;
&#xD;
          -  have one of the following:&#xD;
&#xD;
          -  a positive inhibitor test BU ≥5, OR&#xD;
&#xD;
          -  a Bethesda Unit (BU) &lt;5 but expected to have a high anamnestic response to FVIII or&#xD;
             FIX, as demonstrated from the patient's medical history, precluding the use of factor&#xD;
             VIII or IX products to treat bleeding episodes, OR&#xD;
&#xD;
          -  a BU &lt;5 but expected to be refractory to increased dosing of FVIII or FIX, as&#xD;
             demonstrated from the patient's medical history, precluding the use of factor VIII or&#xD;
             IX products to treat bleeding episodes&#xD;
&#xD;
          -  be aged from birth to &lt;12 years old&#xD;
&#xD;
          -  have experienced at least 3 bleeding episodes of any severity in the past 6 months&#xD;
&#xD;
          -  parents or legal guardians must be capable of understanding and be willing to comply&#xD;
             with the conditions of the protocol&#xD;
&#xD;
          -  parents or legal guardians must have read, understood, and provided written informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have any coagulation disorder other than hemophilia A or B&#xD;
&#xD;
          -  be immunosuppressed (i.e., the patient may not be receiving systemic immunosuppressive&#xD;
             medication; cluster of differentiation 4 (CD4) counts at screening must be &gt;200/µL)&#xD;
&#xD;
          -  have a known allergy or hypersensitivity to rabbits&#xD;
&#xD;
          -  have platelet count &lt;100,000/mL&#xD;
&#xD;
          -  have had a major surgical procedure (e.g. orthopedic, abdominal) within 1 month prior&#xD;
             to first administration of study drug&#xD;
&#xD;
          -  have received an investigational drug within 30 days of first study drug&#xD;
             administration, or be expected to receive such drug during participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jimmy Everest Center for Cancer and Bleeding Disorders</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas / Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot;</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology of Department Hemophilia and Thromboses center</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthwhile Clinical Trials</name>
      <address>
        <city>Benoni</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Specialized Children's Hospital OKHMATDYT, Centre for Hemostatic Pathology (Ukraine)</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <results_first_submitted>July 31, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2020</results_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan: Final Version 2.0</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02448680/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02448680/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Statistical Analysis Plan (v2.0) Addendum</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02448680/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FVIIa: 75 µg/kg First, Then 225 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant) : First Intervention (3 months), Second Intervention (3 months), repeat sequence for entirety of study.</description>
        </group>
        <group group_id="P2">
          <title>FVIIa: 225 µg/kg First, Then 75 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant) : First Intervention (3 months), Second Intervention (3 months), repeat sequence for entirety of study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FVIIa: 75 µg/kg First, Then 225 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant) : First Intervention (3 months), Second Intervention (3 months), repeat sequence for entirety of study.</description>
        </group>
        <group group_id="B2">
          <title>FVIIa: 225 µg/kg First, Then 75 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant) : First Intervention (3 months), Second Intervention (3 months), repeat sequence for entirety of study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="3.02"/>
                    <measurement group_id="B2" value="4.8" spread="3.63"/>
                    <measurement group_id="B3" value="4.9" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age, Categorical</title>
              <category_list>
                <category>
                  <title>Birth to &lt; 6 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 6 years to &lt; 12 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.73" spread="7.432"/>
                    <measurement group_id="B2" value="21.94" spread="13.391"/>
                    <measurement group_id="B3" value="20.88" spread="10.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.21" spread="21.210"/>
                    <measurement group_id="B2" value="108.60" spread="25.904"/>
                    <measurement group_id="B3" value="106.49" spread="23.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.74" spread="2.505"/>
                    <measurement group_id="B2" value="17.35" spread="3.842"/>
                    <measurement group_id="B3" value="17.53" spread="3.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Successfully Treated Mild/Moderate Bleeding Episodes Per FDA Requirement.</title>
        <description>For the primary efficacy endpoint, successful treatment of mild/moderate bleeding episode was defined as meeting all of the following:&#xD;
&quot;Good&quot; or &quot;excellent&quot; response noted by the patient/parent/legal guardian or other caregiver, depending on patient's age and maturity&#xD;
Study drug treatment: No further treatment with LR769 beyond timepoint where a &quot;good&quot; or &quot;excellent&quot; response for this bleeding episode was noted&#xD;
No other hemostatic treatment needed for this bleeding episode&#xD;
No administration of blood products that would indicate continuation of bleeding beyond timepoint where a &quot;good&quot; or &quot;excellent&quot; response for this bleeding episode was noted&#xD;
No increase of pain beyond timepoint where a &quot;good&quot; or &quot;excellent&quot; response for this bleeding episode was noted that could not be explained other than as continuation of bleeding</description>
        <time_frame>12 hours after first administration of study drug</time_frame>
        <population>Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa 225µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Successfully Treated Mild/Moderate Bleeding Episodes Per FDA Requirement.</title>
          <description>For the primary efficacy endpoint, successful treatment of mild/moderate bleeding episode was defined as meeting all of the following:&#xD;
&quot;Good&quot; or &quot;excellent&quot; response noted by the patient/parent/legal guardian or other caregiver, depending on patient's age and maturity&#xD;
Study drug treatment: No further treatment with LR769 beyond timepoint where a &quot;good&quot; or &quot;excellent&quot; response for this bleeding episode was noted&#xD;
No other hemostatic treatment needed for this bleeding episode&#xD;
No administration of blood products that would indicate continuation of bleeding beyond timepoint where a &quot;good&quot; or &quot;excellent&quot; response for this bleeding episode was noted&#xD;
No increase of pain beyond timepoint where a &quot;good&quot; or &quot;excellent&quot; response for this bleeding episode was noted that could not be explained other than as continuation of bleeding</description>
          <population>Treated Population</population>
          <units>Proportion of successfully treated BEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Bleeding Episodes (BEs)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes (BEs)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.654" lower_limit="0.523" upper_limit="0.785"/>
                    <measurement group_id="O2" value="0.603" lower_limit="0.482" upper_limit="0.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Successfully Treated Bleeding Episodes (Mild/Moderate/Severe) Per EMA Definition</title>
        <description>&quot;Good&quot; or &quot;excellent&quot; response noted by the patient/caregiver for mild/moderate bleeding episodes;&#xD;
&quot;Good&quot; or &quot;excellent&quot; response noted by the physician for severe bleeding episodes.</description>
        <time_frame>12 hours after first administration of study drug</time_frame>
        <population>Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa 225 µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Successfully Treated Bleeding Episodes (Mild/Moderate/Severe) Per EMA Definition</title>
          <description>&quot;Good&quot; or &quot;excellent&quot; response noted by the patient/caregiver for mild/moderate bleeding episodes;&#xD;
&quot;Good&quot; or &quot;excellent&quot; response noted by the physician for severe bleeding episodes.</description>
          <population>Treated Population</population>
          <units>Proportion of successfully treated BEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Bleeding Episodes (BEs)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes (BEs)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.667" lower_limit="0.533" upper_limit="0.800"/>
                    <measurement group_id="O2" value="0.625" lower_limit="0.500" upper_limit="0.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-Reported &quot;Good&quot; or &quot;Excellent&quot; Response for Mild/Moderate Bleeding Episodes</title>
        <description>Based on Patient-Reported &quot;Good&quot; or &quot;Excellent&quot; responses as per the below descriptions:&#xD;
Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.&#xD;
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage). No additional infusion of study drug was required.</description>
        <time_frame>12 hour after first administration of study drug</time_frame>
        <population>Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa 225µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-Reported &quot;Good&quot; or &quot;Excellent&quot; Response for Mild/Moderate Bleeding Episodes</title>
          <description>Based on Patient-Reported &quot;Good&quot; or &quot;Excellent&quot; responses as per the below descriptions:&#xD;
Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.&#xD;
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage). No additional infusion of study drug was required.</description>
          <population>Treated Population</population>
          <units>Proportion of successfully treated BEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Bleeding Episodes (BEs)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes (BEs)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.667" lower_limit="0.533" upper_limit="0.800"/>
                    <measurement group_id="O2" value="0.629" lower_limit="0.502" upper_limit="0.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Patient Assessment of a &quot;Good&quot; or &quot;Excellent&quot; Response for Mild/Moderate Bleeding Episodes</title>
        <description>Categories of Response to Treatment are Described as Follows:&#xD;
None: No noticeable effect of the treatment on the bleed or worsening of patient's condition. Continuation of treatment with the study drug was needed.&#xD;
Moderate: Some effect of the treatment on the bleed was noticed, e.g., pain decreased or bleeding signs improved, but bleed continued and required continued treatment with the study drug.&#xD;
Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.&#xD;
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.</description>
        <time_frame>Within 24 hours of Bleeding Episode</time_frame>
        <population>Treated Population with non-missing measurements</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa 225µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Patient Assessment of a &quot;Good&quot; or &quot;Excellent&quot; Response for Mild/Moderate Bleeding Episodes</title>
          <description>Categories of Response to Treatment are Described as Follows:&#xD;
None: No noticeable effect of the treatment on the bleed or worsening of patient's condition. Continuation of treatment with the study drug was needed.&#xD;
Moderate: Some effect of the treatment on the bleed was noticed, e.g., pain decreased or bleeding signs improved, but bleed continued and required continued treatment with the study drug.&#xD;
Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.&#xD;
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.</description>
          <population>Treated Population with non-missing measurements</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Bleeding Episodes with Event</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes with Event</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="8.92" upper_limit="11.83"/>
                    <measurement group_id="O2" value="12.00" lower_limit="11.83" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode</title>
        <description>The number of study drug administrations with non-missing dose information in order to treat one mild/moderate bleeding episode.</description>
        <time_frame>Within 24 hours of Bleeding Episode</time_frame>
        <population>Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa 225µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode</title>
          <description>The number of study drug administrations with non-missing dose information in order to treat one mild/moderate bleeding episode.</description>
          <population>Treated Population</population>
          <units>Administrations of Study Drug</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Bleeding Episodes (BEs)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes (BEs)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.27"/>
                    <measurement group_id="O2" value="2.6" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode</title>
        <description>The total amount of study drug administered in order to treat one mild/moderate bleeding episode.</description>
        <time_frame>Within 24 hours of Bleeding Episode</time_frame>
        <population>Treated Population with non-missing measurements</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa 225µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode</title>
          <description>The total amount of study drug administered in order to treat one mild/moderate bleeding episode.</description>
          <population>Treated Population with non-missing measurements</population>
          <units>mL per bleeding episode</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Bleeding Episodes (BEs)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes (BEs)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.733" spread="6.3693"/>
                    <measurement group_id="O2" value="8.287" spread="5.6531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mild/Moderate Bleeding Episodes With Successful Pain Relief</title>
        <description>Successful pain relief was defined as a Visual Analogue Scale (VAS: 0-100; 0: no pain at all; 100: the worst pain ever possible) pain score at 12 hours after initial study drug administration that was less than the pain score at the start of treatment with study drug.</description>
        <time_frame>12 hour after first administration of study drug</time_frame>
        <population>Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa 225µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Mild/Moderate Bleeding Episodes With Successful Pain Relief</title>
          <description>Successful pain relief was defined as a Visual Analogue Scale (VAS: 0-100; 0: no pain at all; 100: the worst pain ever possible) pain score at 12 hours after initial study drug administration that was less than the pain score at the start of treatment with study drug.</description>
          <population>Treated Population</population>
          <units>Bleeding Episodes (BEs)</units>
          <param>Count of Units</param>
          <units_analyzed>Bleeding Episodes (BEs)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes (BEs)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of the informed consent/assent until resolution or 30 days after the last dose of LR769 or early termination, whichever came first. The average duration for monitoring adverse event is about 11.2 months per patient.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Coagulation Factor VIIa (Recombinant): 75 µg/kg</title>
          <description>75 µg/kg treatment regimen for 3 months&#xD;
Coagulation FVIIa (Recombinant): A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX</description>
        </group>
        <group group_id="E2">
          <title>Coagulation Factor VIIa (Recombinant): 225 µg/kg</title>
          <description>225 µg/kg treatment regimen for 3 months&#xD;
Coagulation FVIIa (Recombinant): A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dysentery</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresis</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>Term from vocabulary, MedDRA 15.1</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kerry Biron, Director US Clinical Operations</name_or_title>
      <organization>LFB USA, Inc.</organization>
      <phone>508-370-5166</phone>
      <email>kerry.biron@lfb-usa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

